Latest News about Phase 3 Trial
Recent news which mentions Phase 3 Trial
Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia
February 08, 2022
Tickers
ALKS
From Benzinga
Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder Studies
February 08, 2022
Tickers
CING
From Benzinga
Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation
January 25, 2022
Tickers
ACHV
From Benzinga
Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients
January 24, 2022
Tickers
LYRA
From Benzinga
On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial
January 24, 2022
Tickers
SABS
From Benzinga
FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease Progression
January 24, 2022
Tickers
GILD
From Benzinga
From Benzinga
Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection
January 20, 2022
Tickers
MCRB
From Benzinga
EQRx's Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings
January 19, 2022
Tickers
EQRX
From Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
January 19, 2022
From Benzinga
Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory Trial
January 19, 2022
Tickers
MRK
From Benzinga
RedHill Biopharma's Oral COVID-19 Treatment Improves Median Time To Viral RNA Clearance
January 13, 2022
Tickers
RDHL
From Benzinga
Merck's Keytruda As Adjuvant Treatment Improves Disease-Free Survival In Lung Cancer Setting
January 10, 2022
Tickers
MRK
From Benzinga
Oncternal, FDA In Pact For Pivotal Study Design For Zilovertam In Mantle Cell Lymphoma
January 05, 2022
Tickers
ONCT
From Benzinga
Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19
December 23, 2021
Tickers
GILD
From Benzinga
Allakos' Shares Nosedive After Lirentelimab Studies Fail To Achieve Statistical Significance On Symptomatic Endpoints
December 22, 2021
Tickers
ALLK
From Benzinga
Valneva Posts Positive Lot-to-Lot Consistency Data For Its Single-Dose Chikungunya Vaccine
December 22, 2021
Tickers
VALN
From Benzinga
DBV Technologies To Conduct New Pivotal Trial For Peanut Allergy Patch, Shares Plunge To 52-Week Low
December 21, 2021
Tickers
DBVT
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
|
|
|